Characterization in Vitro and Engraftment Potential in Vivo of Human Progenitor T Cells Generated from Hematopoietic Stem Cells
Overview
Authors
Affiliations
T-cell development follows a defined set of stage-specific differentiation steps. However, molecular and cellular events occurring at early stages of human T-cell development remain to be fully elucidated. To address this, human umbilical cord blood (UCB) hematopoietic stem cells (HSCs) were induced to differentiate to the T lineage in OP9-DL1 cocultures. A developmental program involving a sequential and temporally discrete expression of key differentiation markers was revealed. Quantitative clonal analyses demonstrated that CD34(+)CD38(-) and CD34(+)CD38(lo) subsets of UCB contain a similarly high T-lineage progenitor frequency, whereas the frequency in CD34(+)CD38(+/hi) cells was 5-fold lower. Delta-like/Notch-induced signals increased the T-cell progenitor frequency of CD34(+)CD38(-/lo) cells differentiated on OP9-DL1, and 2 distinct progenitor subsets, CD34(+)CD45RA(+)CD7(++)CD5(-)CD1a(-) (proT1) and CD34(+)CD45RA(+)CD7(++)CD5(+)CD1a(-) (proT2), were identified and their thymus engrafting capacity was examined, with proT2 cells showing a 3-fold enhanced reconstituting capacity compared with the proT1 subset. Furthermore, in vitro-generated CD34(+)CD7(++) progenitors effectively engrafted the thymus of immunodeficient mice, which was enhanced by the addition of an IL-7/IL-7 antibody complex. Taken together, the identification of T-progenitor subsets readily generated in vitro may offer important avenues to improve cellular-based immune-reconstitution approaches.
T Cell Development: From T-Lineage Specification to Intrathymic Maturation.
Golzari-Sorkheh M, Yoganathan K, Chen E, Singh J, Zuniga-Pflucker J Adv Exp Med Biol. 2025; 1471:81-137.
PMID: 40067585 DOI: 10.1007/978-3-031-77921-3_4.
Generation of autologous hematopoietic stem cell-derived T lymphocytes for cancer immunotherapy.
Maneechai K, Khopanlert W, Noiperm P, Udomsak P, Viboonjuntra P, Julamanee J Heliyon. 2024; 10(19):e38447.
PMID: 39398019 PMC: 11467635. DOI: 10.1016/j.heliyon.2024.e38447.
Li F, Zhu Y, Wang T, Tang J, Huang Y, Gu J Cell Regen. 2024; 13(1):9.
PMID: 38630195 PMC: 11024070. DOI: 10.1186/s13619-024-00192-z.
Rai R, Steinberg Z, Romito M, Zinghirino F, Hu Y, White N Hum Gene Ther. 2024; 35(7-8):269-283.
PMID: 38251667 PMC: 11698663. DOI: 10.1089/hum.2023.100.
Engineering T Cell Development for the Next Generation of Stem Cell-Derived Immunotherapies.
Michaels Y, Durland L, Zandstra P GEN Biotechnol. 2023; 2(2):106-119.
PMID: 37928777 PMC: 10624212. DOI: 10.1089/genbio.2023.0008.